Timothy Chiang
Stock Analyst at Capital One
(0.22)
# 4,200
Out of 4,876 analysts
6
Total ratings
16.67%
Success rate
-11.2%
Average return
Main Sectors:
Stocks Rated by Timothy Chiang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANIP ANI Pharmaceuticals | Initiates: Overweight | n/a | $65.50 | - | 1 | Mar 15, 2024 | |
| AKYA Akoya Biosciences | Initiates: Overweight | $19 | $1.24 | +1,432.26% | 1 | Nov 3, 2022 | |
| PTGX Protagonist Therapeutics | Initiates: Buy | $55 | $55.69 | -1.24% | 2 | Feb 11, 2022 | |
| AMPH Amphastar Pharmaceuticals | Upgrades: Outperform | n/a | $23.08 | - | 1 | Oct 5, 2020 | |
| IDYA IDEAYA Biosciences | Initiates: Outperform | $28 | $21.37 | +31.02% | 1 | Sep 1, 2020 |
ANI Pharmaceuticals
Mar 15, 2024
Initiates: Overweight
Price Target: n/a
Current: $65.50
Upside: -
Akoya Biosciences
Nov 3, 2022
Initiates: Overweight
Price Target: $19
Current: $1.24
Upside: +1,432.26%
Protagonist Therapeutics
Feb 11, 2022
Initiates: Buy
Price Target: $55
Current: $55.69
Upside: -1.24%
Amphastar Pharmaceuticals
Oct 5, 2020
Upgrades: Outperform
Price Target: n/a
Current: $23.08
Upside: -
IDEAYA Biosciences
Sep 1, 2020
Initiates: Outperform
Price Target: $28
Current: $21.37
Upside: +31.02%